CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 HLA-G 的 CAR-T 细胞作为 EGFR 突变及过表达口腔癌的有效治疗策略
英文原题：CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.
查看英文原题
CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
口腔鳞状细胞癌（OSCC）是全球常见的恶性肿瘤。近期，科学家重点研究肿瘤调控相关治疗策略，并设计针对特定靶点的分子。一些研究已显示，人白细胞抗原G（HLA-G）在恶性肿瘤中的临床意义，以及NLR家族含pyrin结构域蛋白3（NLRP3）炎症小体促进OSCC肿瘤发生的作用。本研究首次探究异常表皮生长因子受体（EGFR）是否通过NLRP3炎症小体介导的IL-1分泌诱导OSCC中HLA-G表达。结果显示，NLRP3炎症小体上调会使FaDu细胞胞质和细胞膜中HLA-G大量表达。此外，我们还制备了抗HLA-G嵌合抗原受体（CAR）T细胞，并提供证据显示其对EGFR突变及过表达口腔癌的作用。我们的结果可与OSCC患者数据整合，推动基础研究转化为临床意义，并可能促成针对EGFR异常OSCC的新疗法。
展开英文摘要原文
Oral squamous cell carcinoma (OSCC) is a common malignancy in the world. Recently, scientists have focused on therapeutic strategies to determine the regulation of tumors and design molecules for specific targets.
Some studies have demonstrated the clinical significance of human leukocyte antigen G (HLA-G) in malignancy and NLR family pyrin domain-containing 3 (NLRP3) inflammasome in promoting tumorigenesis in OSCC. This is the first study to investigate whether aberrant epidermal growth factor receptor (EGFR) induces HLA-G expression through NLRP3 inflammasome-mediated IL-1 secretion in OSCC.
Our results showed that the upregulation of NLRP3 inflammasome leads to abundant HLA-G in the cytoplasm and cell membrane of FaDu cells.
In addition, we also generated anti-HLA-G chimeric antigen receptor (CAR)-T cells and provided evidence for their effects in EGFR-mutated and overexpressed oral cancer.
Our results may be integrated with OSCC patient data to translate basic research into clinical significance and may lead to novel EGFR-aberrant OSCC treatment.
论文信息
- 作者
- Lin YC、Hua CH、Lu HM、Huang SW、Chen Y、Tsai MH、Lin FY、Canoll P
- 第一作者单位
- Drug Development Center, China Medical University, Taichung 404, Taiwan.China
- 通讯作者单位
- Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.Taiwan
- 期刊
- iScience2023 Mar 17
- 原文标识
- PubMed 36876120 · DOI 10.1016/j.isci.2023.106089
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →